AUBREY STANLEY: Open Payments
NPI 1912373895 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$957 in 58 payments from 13 companies in 2025. Trend: 2023 $1,206 · 2024 $1,006 · 2025 $957
Food & beverage: $957
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $227 |
| Novo Nordisk Inc | 14 | $215 |
| AstraZeneca Pharmaceuticals LP | 7 | $139 |
| GlaxoSmithKline, LLC. | 4 | $86 |
| Lilly USA, LLC | 3 | $67 |
| Amgen Inc. | 3 | $47 |
| PFIZER INC. | 2 | $38 |
| Corcept Therapeutics | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 1 | $33 |
| SANOFI-AVENTIS U.S. LLC | 1 | $20 |
Products named: QULIPTA, Rybelsus, TRELEGY ELLIPTA, MOUNJARO, UBRELVY, VRAYLAR, FARXIGA, BREZTRI.
Industry payments across TX — which companies pay providers there.
